双环脲类化合物作为治疗血液系统癌症的JAK2抑制剂
Bicyclic Ureas as JAK2 Inhibitors for Treating Hematological Cancer.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Oct 29;15(11):1824-1825. doi: 10.1021/acsmedchemlett.4c00496. eCollection 2024 Nov 14.
Abstract
Provided herein are novel bicyclic ureas as JAK2 inhibitors, pharmaceutical compositions, use of such compounds in treating hematological cancer, and processes for preparing such compounds.
摘要
本文提供了作为JAK2抑制剂的新型双环脲、药物组合物、此类化合物在治疗血液系统癌症中的用途以及制备此类化合物的方法。
相似文献
1
Bicyclic Ureas as JAK2 Inhibitors for Treating Hematological Cancer.双环脲类化合物作为治疗血液系统癌症的JAK2抑制剂
ACS Med Chem Lett. 2024 Oct 29;15(11):1824-1825. doi: 10.1021/acsmedchemlett.4c00496. eCollection 2024 Nov 14.
2
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.作为用于治疗癌症的CD73抑制剂的新型双环杂环化合物。
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
3
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.新型双环杂环化合物作为治疗炎症性疾病的MRGPRX2拮抗剂
ACS Med Chem Lett. 2025 Jun 2;16(6):980-981. doi: 10.1021/acsmedchemlett.5c00305. eCollection 2025 Jun 12.
4
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
5
Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.作为用于治疗癌症的细胞外信号调节激酶5（ERK5）抑制剂的吡咯并吡嗪化合物
ACS Med Chem Lett. 2024 Dec 11;16(1):16-17. doi: 10.1021/acsmedchemlett.4c00580. eCollection 2025 Jan 9.
6
Novel Indazole Compounds as PKMYT1 Kinase Inhibitors for Treating Cancer.新型吲唑化合物作为治疗癌症的PKMYT1激酶抑制剂
ACS Med Chem Lett. 2024 Oct 12;15(11):1810-1811. doi: 10.1021/acsmedchemlett.4c00486. eCollection 2024 Nov 14.
7
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
8
Novel Phenylpiperidine Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer or Fibrotic Diseases.新型苯基哌啶衍生物作为QPCT和QPCTL抑制剂用于治疗癌症或纤维化疾病。
ACS Med Chem Lett. 2024 Oct 30;15(11):1826-1827. doi: 10.1021/acsmedchemlett.4c00495. eCollection 2024 Nov 14.
9
Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes.新型氰基吡啶化合物作为治疗非酒精性脂肪性肝病、非酒精性脂肪性肝炎和II型糖尿病的KHK抑制剂
ACS Med Chem Lett. 2024 Jul 23;15(8):1191-1192. doi: 10.1021/acsmedchemlett.4c00332. eCollection 2024 Aug 8.
10
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.作为用于治疗阿尔茨海默病和帕金森病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 29;15(8):1203-1204. doi: 10.1021/acsmedchemlett.4c00343. eCollection 2024 Aug 8.
本文引用的文献
1
Unveiling the pathological functions of SOCS in colorectal cancer: Current concepts and future perspectives.揭示 SOCS 在结直肠癌中的病理功能：当前概念和未来展望。
Pathol Res Pract. 2024 Oct;262:155564. doi: 10.1016/j.prp.2024.155564. Epub 2024 Aug 28.
2
Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure-activity relationship.含氮杂环类作为 Janus 激酶（JAK）抑制剂的抗癌活性的治疗潜力：生物活性、选择性和构效关系。
Bioorg Chem. 2024 Nov;152:107696. doi: 10.1016/j.bioorg.2024.107696. Epub 2024 Aug 8.
3
Renal cancer: signaling pathways and advances in targeted therapies.肾癌：信号通路与靶向治疗进展
MedComm (2020). 2024 Aug 1;5(8):e676. doi: 10.1002/mco2.676. eCollection 2024 Aug.
4
Health benefits of fraxetin: From chemistry to medicine.蛇床素的健康益处：从化学到医学。
Arch Pharm (Weinheim). 2024 Jul;357(7):e2400092. doi: 10.1002/ardp.202400092. Epub 2024 Mar 19.
Zotero 插件